Grant will fund joint research by Imperial College, London and Oxford Vacmedix into antimicrobial resistance, in collaboration with the Ditan Hospital in Beijing, China Oxford, UK – 19th December 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focusing on the development of cancer vaccines, announced today the award of an Innovate UK grant …
Oxford Vacmedix appoints Belgium based Eurofins CDMO to carry out the GMP manufacturing of the lead immunotherapy cancer vaccine OVM-200, to support Phase 1 application. Oxford, UK – 22nd November 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that Eurofins CDMO based in Belgium …
Grant to fund research into novel applications and development of new cancer vaccines using the recombinant overlapping peptide technology developed by Dr. Shisong Jiang. Oxford, UK – 9th July 2019 Oxford Vacmedix (OVM), the UK based biopharma company, focused on the development of a new generation of cancer vaccines, announced today that research into its …
Oxford Vacmedix announces Research Collaboration with University of Oxford Read More »
CHAIN Biotechnology and University of Oxford have been awarded grant funding to develop live biotherapeutics that support oral delivery of Oxford Vacmedix’s immunotherapy cancer vaccines. Oxford, UK – 2nd July 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today the award of an Innovate UK …
Cancer vaccine firm Oxford Vacmedix announces collaboration and Innovate UK grant Read More »
Oxford Vacmedix appoints Belgium based Xpress Biologics to carry out the GLP manufacturing of both lead immunotherapy cancer vaccines, to support Phase 1 applications. Oxford, UK – 8th February 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that Xpress Biologics based in Belgium has …
Leading international experts advise Oxford Vacmedix on development programme Oxford, UK – 31st January 2019 Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announces today the first meeting of its Scientific Advisory Council. World-class experts gathered to guide the research and preclinical development programmes of the company …
Cancer vaccine firm Oxford Vacmedix holds first meeting of Scientific Advisory Council Read More »
Appointment brings further expertise in immunology and pharmaceutical development to Oxford Vacmedix Oxford 12th October 2018; Oxford Vacmedix, the UK-based biopharma company focused on the development of cancer vaccines announced today that Professor Xiao-Ning Xu will join the company’s Scientific Advisory Council. Professor Xu is an immunologist who was previously a research leader at the …
Professor Xiao-Ning Xu joins Scientific Advisory Council of Oxford Vacmedix Read More »
World-class immunologist to advise Oxford Vacmedix on development of novel cancer vaccines. Oxford Vacmedix, a UK-based biopharma company focused on the development of cancer vaccines, announced today that Professor Sir Andrew McMichael will join the company’s Scientific Advisory Council. Sir Andrew is an immunologist, Emeritus Professor, former Professor of Molecular Medicine, and previously Director of …
Professor Sir Andrew McMichael joins Scientific Advisory Council of Oxford Vacmedix Read More »
Directors join Oxford Vacmedix from Myongji Hospital Group and Series A investors Cancer ROP in South Korea and Mr Jin from China. Oxford Vacmedix UK Limited (OVM), the UK-‐based biopharma company focused on the development of cancer vaccines, confirmed today the appointment of new Directors to the Board. These new appointments follow the successful Series …
Cancer vaccine firm Oxford Vacmedix confirms appointment of new Directors Read More »
Oxford Vacmedix appoints Shanghai based PharmaLegacy to carry out the proof of concept work of both lead immunotherapy cancer vaccines, to support Phase 1 applications. Oxford Vacmedix UK Limited (OVM), the UK-based biopharma company focused on the development of cancer vaccines, announced today that PharmaLegacy of Shanghai, China has been appointed to complete the proof …